Graphene-based hemostatic sponge

Wu, Bingxin; Du, Fanglin; Wenjing, A; Li, Guofeng; Wang, Xing

doi:10.1016/j.cclet.2021.06.029

Cited by 16 publications

(7 citation statements)

References 104 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Due to the mediating action of von Willebrand factor (vWf) (Flood, 2015), platelets can adhere to collagen underneath the vascular endothelium, forming the initial thrombus. At the same time, due to vascular injury, the integrity of the vascular wall is destroyed, exposing tissue factor (TF) in the adventitia to the blood, thereby activating the extrinsic coagulation pathway (Wu et al, 2022). Subsequently, at the wound site, the formation of the TF-FVIIa (Grover and Mackman, 2018) complex promotes the activation of Factor X (FX) to Factor Xa (FXa), which also requires the help of Ca 2+ and other cofactors.…”

Section: Coagulation Processmentioning

confidence: 99%

Discovery and development of Factor Xa inhibitors (2015–2022)

Zheng

Dai

et al. 2023

Front. Pharmacol.

View full text Add to dashboard Cite

As a pathological coagulation process, thrombus can lead to many serious diseases, including ischemic stroke, acute myocardial infarction (AMI), acute coronary syndrome (ACS), and deep venous thrombosis (DVT). And anticoagulant drugs are one of the most effective ways to prevent and treat these diseases. Although macromolecular anticoagulant drugs such as low molecular weight heparins (LMWHs) are widely used in the clinic, their characteristics of requiring injectable use hinder their further promotion in the clinic, and the disadvantages of oral anticoagulant drugs, such as warfarin and dabigatran etexilate, which can easily cause bleeding adverse effects, are also not addressed. Factor Xa (FXa) has gained attention because it lies at the intersection of the coagulation cascade pathways, whereas subsequently introduced Factor Xa inhibitors such as rivaroxaban and apixaban, among others, have gained market popularity because of their high potency for anticoagulation and high specificity for Factor Xa when administered orally. But some of the drawbacks that these Factor Xa inhibitors have simultaneously such as fewer indications and the lack of an effective reversal drug when bleeding occurs are urgently addressed. The development of new Factor Xa inhibitors therefore becomes one means of addressing these questions. This article summarizes the small molecule Factor Xainhibitors developed from 2015 to 2022, classifies them according to their scaffolds, focuses on the analysis of their structure-activity relationships, and provides a brief assessment of them.

show abstract

Section: Coagulation Processmentioning

confidence: 99%

Discovery and development of Factor Xa inhibitors (2015–2022)

Zheng

Dai

et al. 2023

Front. Pharmacol.

View full text Add to dashboard Cite

show abstract

“…CMs with good swelling capacity can rapidly absorb water from blood, increasing the concentration of coagulation pro- teins and reducing the blood flow rate, thereby promoting blood coagulation. 56 According to the swelling capacity, layered CMs can be divided into three categories: non-swelling CMs, swelling CMs, and partially swelling CMs.…”

Section: Lamellar Morphologymentioning

confidence: 99%

Progress and future prospects of hemostatic materials based on nanostructured clay minerals

Yang,

Wang,

Yang

et al. 2023

Biomater. Sci.

View full text Add to dashboard Cite

show abstract

“…In addition, some substances rich in carboxyl groups have the ability to clot the blood. For instance, graphene oxide (GO) is a two-dimensional material with abundant oxygen-containing groups, e.g., hydroxyl and epoxy groups on the surface, and carboxyl groups on the edges [ 128 , 129 ]. Li et al.…”

Section: Molecular Structure Design Of the Hemostasis Materialsmentioning

confidence: 99%

Design of biopolymer-based hemostatic material: Starting from molecular structures and forms

Zou¹,

Li²,

Hu³

et al. 2022

Materials Today Bio

View full text Add to dashboard Cite

Graphene-based hemostatic sponge

Cited by 16 publications

References 104 publications

Discovery and development of Factor Xa inhibitors (2015–2022)

Discovery and development of Factor Xa inhibitors (2015–2022)

Progress and future prospects of hemostatic materials based on nanostructured clay minerals

Design of biopolymer-based hemostatic material: Starting from molecular structures and forms

Contact Info

Product

Resources

About